Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Fig. 5

Ex vivo testing of niraparib, SN38, and their combination on human primary CRC 3D cell cultures (spheroids) according to the genetic background. Five primary 3D cell cultures (spheroids) were generated from surgical specimens (primary tumor or metastasis) of colorectal cancer. Tumor specimens were genetically profiled using a comprehensive genomic panel encompassing 324 frequently mutated cancer genes. Growth inhibition is significantly improved in IC-006 (ATM-mutated) at two concentration levels and in IC-011 (CHEK2-mutated). *p < 0.05; **: p < 0.01

Back to article page